Free tool
FAERS Monitor: Cefazolin Sodium
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211413 or its brand name (Cefazolin Sodium, Cefazolin Sodium). Reports on generic versions are filed under their own applications.
Reports
12,207
Serious
11,391
93% of reports
Hospitalization
6,181
Death reported
1,402
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hypotension711
- drug ineffective679
- anaphylactic reaction659
- anaphylactic shock622
- rash600
- pyrexia518
- renal failure488
- acute kidney injury442
- off label use424
- pain417
- nausea379
- urticaria361
- dyspnoea337
- drug hypersensitivity329
- erythema320
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 222 |
| 2005 | 210 |
| 2006 | 255 |
| 2007 | 157 |
| 2008 | 238 |
| 2009 | 224 |
| 2010 | 233 |
| 2011 | 507 |
| 2012 | 462 |
| 2013 | 268 |
| 2014 | 304 |
| 2015 | 373 |
| 2016 | 540 |
| 2017 | 510 |
| 2018 | 700 |
| 2019 | 831 |
| 2020 | 855 |
| 2021 | 805 |
| 2022 | 954 |
| 2023 | 1,008 |
| 2024 | 981 |
| 2025 | 956 |
| 2026 | 614 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,952 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anaphylactic shockSignal | 622 | 42.6 | 39.4 | 24,639 |
| anaphylactic reactionSignal | 659 | 20.8 | 19.3 | 12,276 |
| renal failureSignal | 488 | 6.4 | 5.8 | 2,201 |
| hypotensionSignal | 711 | 6.1 | 5.7 | 3,063 |
| acute kidney injurySignal | 442 | 5.0 | 4.6 | 1,412 |
| urticariaSignal | 361 | 3.7 | 3.4 | 719 |
| drug hypersensitivitySignal | 329 | 2.9 | 2.6 | 420 |
| erythemaSignal | 320 | 2.7 | 2.4 | 339 |
| pyrexiaSignal | 518 | 2.6 | 2.4 | 508 |
| rashSignal | 600 | 2.4 | 2.2 | 485 |
| pain | 417 | 1.2 | 1.1 | 10 |
| dyspnoea | 337 | 1.0 | 0.9 | 0 |
| drug ineffective | 679 | 0.9 | 0.8 | 10 |
| off label use | 424 | 0.8 | 0.8 | 14 |
| nausea | 379 | 0.8 | 0.7 | 14 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.